Total Payments
$1,898
2024 Payments
$522.62
Companies
19
Transactions
62
Medicare Patients
855
Medicare Billing
$333,551
Payment Breakdown by Category
Food & Beverage$1,898 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,898 | 62 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $499.50 | 24 | $0 (2024) |
| Medtronic, Inc. | $273.26 | 4 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $194.08 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $132.72 | 1 | $0 (2023) |
| Phathom Pharmaceuticals, Inc. | $119.25 | 1 | $0 (2024) |
| W. L. Gore & Associates, Inc. | $98.20 | 1 | $0 (2024) |
| Celgene Corporation | $92.19 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $90.32 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $89.25 | 1 | $0 (2023) |
| Boston Scientific Corporation | $76.39 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $522.62 | 14 | Phathom Pharmaceuticals, Inc. ($119.25) |
| 2023 | $1,193 | 45 | AbbVie Inc. ($242.64) |
| 2022 | $161.94 | 2 | ABBVIE INC. ($161.94) |
| 2020 | $20.35 | 1 | AbbVie Inc. ($20.35) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/21/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | W. L. Gore & Associates, Inc. | GORE VIABAHN VBX Balloon Expandable Endo (Device) | Food and Beverage | In-kind items and services | $98.20 | General |
| Category: Devices | ||||||
| 06/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $119.25 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.30 | General |
| Category: Neuroscience | ||||||
| 05/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: IMMUNOLOGY | ||||||
| 05/06/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: IMMUNOLOGY | ||||||
| 04/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/17/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Neuroscience | ||||||
| 03/26/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.57 | General |
| Category: Neuroscience | ||||||
| 03/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/22/2024 | Olympus America Inc. | EVIS EXERA III COLONOVIDEOSCOPE (Device) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Gastroenterology | ||||||
| 02/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.19 | General |
| Category: Neuroscience | ||||||
| 02/08/2024 | Medtronic, Inc. | HAWKONE (Device) | Food and Beverage | In-kind items and services | $110.50 | General |
| Category: Directional Atherectomy Devices | ||||||
| 02/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/08/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.46 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/15/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Immunology | ||||||
| 11/15/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.06 | General |
| Category: Neuroscience | ||||||
| 10/31/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $20.35 | General |
| Category: GI | ||||||
| 10/28/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/24/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.25 | General |
| Category: Neuroscience | ||||||
| 10/05/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/04/2023 | Medtronic, Inc. | HAWKONE (Device) | Food and Beverage | In-kind items and services | $94.76 | General |
| Category: Directional Atherectomy Devices | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 855 | 13,381 | $1.9M | $333,551 |
Total Patients
855
Total Services
13,381
Medicare Billing
$333,551
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 17 | 9,300 | $483,600 | $162,148 | 33.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 21 | 3,110 | $718,410 | $80,626 | 11.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 81 | 84 | $119,784 | $16,985 | 14.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 86 | 88 | $40,040 | $8,984 | 22.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 78 | 129 | $30,573 | $8,075 | 26.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 117 | 119 | $141,610 | $8,023 | 5.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $37,398 | $7,649 | 20.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 53 | $53,000 | $5,236 | 9.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 51 | $17,748 | $5,080 | 28.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 28 | 28 | $42,000 | $3,912 | 9.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 46 | 46 | $68,843 | $3,846 | 5.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 42 | 42 | $14,406 | $2,792 | 19.4% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 25 | 25 | $30,670 | $2,671 | 8.7% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 16 | 17 | $36,202 | $2,508 | 6.9% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 15 | 15 | $16,310 | $2,371 | 14.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 24 | $8,256 | $2,260 | 27.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 11 | 11 | $11,790 | $1,920 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 26 | $6,162 | $1,829 | 29.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 35 | $7,805 | $1,700 | 21.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 33 | 39 | $5,109 | $1,547 | 30.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $5,728 | $1,407 | 24.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $13,419 | $1,119 | 8.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 40 | $12,000 | $862.00 | 7.2% |
About Dr. Page Axley, M.D
Dr. Page Axley, M.D is a Gastroenterology healthcare provider based in Pensacola, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2016. The National Provider Identifier (NPI) number assigned to this provider is 1245693613.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Page Axley, M.D has received a total of $1,898 in payments from pharmaceutical and medical device companies, with $522.62 received in 2024. These payments were reported across 62 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($1,898).
As a Medicare-enrolled provider, Axley has provided services to 855 Medicare beneficiaries, totaling 13,381 services with total Medicare billing of $333,551. Data is available for 1 year (2023–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Pensacola, FL
- Active Since 04/01/2016
- Last Updated 05/17/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1245693613
Products in Payments
- HAWKONE (Device) $273.26
- RINVOQ (Biological) $232.02
- ZEPOSIA (Drug) $224.91
- DUPIXENT (Biological) $216.77
- SKYRIZI (Biological) $141.99
- VOQUEZNA (Drug) $119.25
- GORE VIABAHN VBX Balloon Expandable Endo (Device) $98.20
- Epclusa (Drug) $89.25
- GATTEX (Drug) $66.05
- Linzess (Drug) $58.85
- LINZESS (Drug) $42.47
- IBSRELA (Drug) $36.23
- VIBERZI (Drug) $31.43
- CREON (Drug) $31.24
- STELARA (Biological) $24.66
- ENTYVIO (Biological) $24.27
- AVSOLA (Biological) $21.19
- HADLIMA (Drug) $20.76
- HUMIRA (Biological) $20.35
- XIFAXAN (Drug) $19.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Pensacola
Dr. Benjamin Tharian, Md Mrcp Fracp, MD MRCP FRACP
Gastroenterology — Payments: $42,592
Gastroenterology $42,592
Frederic Newman, Md, MD
Gastroenterology — Payments: $32,704
Gastroenterology $32,704
Dr. Michael Zelig, Md, MD
Gastroenterology — Payments: $10,262
Gastroenterology $10,262
Dr. Donald Denby, M.d, M.D
Gastroenterology — Payments: $9,755
Gastroenterology $9,755
Dr. Ronald Powell, Md, MD
Gastroenterology — Payments: $8,112
Gastroenterology $8,112
Patrick Reilly, Md, MD
Gastroenterology — Payments: $6,928
Gastroenterology $6,928